GGT1 and neoplasm: Increased GST and/or γGT tumor expression, generally considered as a bad prognosis marker (associated with drug resistance and disease progression), and could potentially be used as a predictive marker, allowing doctors, after biopsy, to identify which patients will respond best to GST or γGT-activated prodrugs.